Navigation Links
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Date:4/14/2008

en.com.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen Inc. SuperGen Inc.

SVP, Corporate Communications & Business Manager, Investor

Development Relations

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
6. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Research and Markets ... Advanced Wound Care and Closure Market (Types, Applications, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. The ... closure market (types, applications, end user and geography) ...
(Date:8/20/2014)... Aug. 20, 2014   Ventana Medical Systems, ... today announced that its VENTANA System for Primary ... the European Union for routine pathology, including primary ... of VENTANA Virtuoso software coupled with either the ... slide scanner, provides automated digital slide creation, case ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: Global Coatings for Medical ... This report analyzes the worldwide ... Million by the following Product Segments: Active Coatings, ... report provides separate comprehensive analytics for the US, ...
Breaking Medicine Technology:Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
(Date:8/20/2014)... According to an order signed by ... the multicounty litigation (MCL) case pending in the Superior ... IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 lawsuits against DePuy ... prejudice. The cases enumerated in the order of the ... Rottenstein Law Group LLP, a national personal injury law ...
(Date:8/20/2014)... August 20, 2014 Ticket Down is ... in Miami, FL at the Sun Life Stadium in early September. ... this September when Brazil and Colombia meet at Sun Life Stadium ... top 10 teams in the world and will be a rematch ... The match will kick-off on Sept. 5 and will feature some ...
(Date:8/20/2014)... both breast cancer relapses and responses to chemotherapy, ... newly found marker could help doctors classify each ... that is more effective. The discovery was a ... Molecular and Cell Biology (IMCB), and the Cancer ... National University of Singapore (NUS). , Despite advancements ...
(Date:8/20/2014)... FL (PRWEB) August 20, 2014 IQ ... today was named to the Inc. 500 , distinguishing ... the United States. IQ Formulations not only made the list, ... than 5,486 percent over the past three years. It also ... the state of Florida and the second fastest growing company ...
(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3
... ... Interim Leadership division as senior vice president. A seasoned executive with nearly 20 years of ... , ... 2009 -- B. E. Smith recently hired Deirdre Byrne to lead the firm’s ...
... , MIAMI, Dec. 17 Physicians Healthcare ... today announced that it has issued its financial statements for ... being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer ...
... the employment and sociodemographic characteristics involved in the exposure of ... often work standing up or have to lift heavy objects, ... are frequently exposed to some physical risk in their place ... to exposure to workplace hazards", M Carmen Gonzlez, lead author ...
... PITTSBURGH, Dec. 17 Stem cells that could one day ... easily harvested from the tissue of the umbilical cord, just ... to treat some blood disorders, said University of Pittsburgh School ... the Journal of Biomedicine and Biotechnology . ...
... ... Online , ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun for Villanova’s newly online ... schedules can’t accommodate a campus-based program. With the university’s Master of Science in Human ...
... 17 CareFusion Corporation (NYSE: CFN ) announced today ... TRC Capital Corporation (TRC) to purchase up to four million shares ... of common stock outstanding. TRC,s offer price of $23.50 per share ... stock on Dec. 14, 2009, the last full trading day prior ...
Cached Medicine News:Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: